(May 28, 2020, 12:17 PM EDT) -- DENVER — Although five drug companies presented “persuasive arguments,” a 10th Circuit U.S. Court of Appeals panel on May 26 denied a motion for an interlocutory appeal of the certification of two classes of purchasers of the EpiPen epinephrine autoinjector (Pfizer, Inc., et al. v. All Plaintiffs, No. 20-603, 10th Cir.)....